ArticleScience advances2026
Ex vivo bone marrow subniches influence the fate of human antibody-secreting cells.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Long-term humoral immunity relies on long-lived plasma cells in the bone marrow (BM). However, the processes governing plasma cell transport, positioning, and longevity within the BM niche remain poorly understood, especially in humans. Most existing knowledge comes from mouse studies or limited human-based models, which makes translating findings to human biology challenging. Here, we introduce a physiologically relevant human bone marrow-on-a-chip (hBMOC) model to investigate the behavior and interactions of human immune organoid-derived antibody-secreting cells (ASCs) within the human BM microenvironment. The hBMOC model is microvascular and perfusable and incorporates both endosteal and perivascular niches. We demonstrate that human ASCs migrate through blood vessels, accumulating and clustering in perivascular areas where they are closely associated with critical survival factors. In addition, we found that the presence of the endosteal niche substantially affects human ASC survival, movement, and retention, underscoring the dynamic interactions among human BM subniches that regulate ASC activity. We observed that a subset of human ASCs exhibits a dynamic stop-and-go migration pattern partially regulated by CXCR4-CXCL12 signaling. These findings provide direct insight into human ASC biology that has remained poorly defined, including their niche-specific localization, survival, and migratory dynamics within a three-dimensional human bone marrow microenvironment. Our results emphasize the distinct and cooperative roles of perivascular and endosteal compartments in supporting human ASC fate, offering previously inaccessible mechanistic insights into how human BM niches regulate plasma cells. This work lays the groundwork for studying plasma cell aging, vaccine durability, and disease-related dysfunction in human ASC maintenance and persistence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.